Arcus and Summit team up to test kidney cancer drug combo

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. AXP

Go back to Arcus and Summit team up to test kidney cancer drug combo

Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

July 22, 2026 4:30 PM EDT

Data Expected to Be Generated by Mid-2027

HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs, today announced a clinical trial collaboration to evaluate the safety and efficacy of Arcuss casdatifan, an... More